The Differential Diagnosis of Hypercalcemia

The Parathyroids: Basic and Clinical Concepts: Third Edition

Volumn , Issue , 2014, Pages 606-616

  Streeten, Elizabeth A ^a   Jaimungal, Sarada ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

CYP24A1 mutation; Granulomatous infection; Malignant solid tumors; Milk alkali syndrome; Multiple myeloma; Non malignant tissue production; Williams syndrome

Indexed keywords

EID: 84942765510     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397166-1.00041-2     Document Type: Chapter

References (101)

1. Silverberg S.J., Walker M.D., Bilezikian J.P. Asymptomatic primary hyperparathyroidism. J Clin Densitom 2013, 16:14-21.
2. Yeh M.W., Ituarte P.H., Zhou H.C., Nishimoto S., Liu I.L., Harari A., et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013, 98:1122-1129.
3. Rejnmark L., Vestergaard P., Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011, 96:2377-2385.
4. French S., Subauste J., Geraci S. Calcium abnormalities in hospitalized patients. South Med J 2012, 105:231-237.
5. Walker M.D., Rubin M., Silverberg S.J. Nontraditional manifestations of primary hyperparathyroidism. J Clin Densitom 2013, 16:40-47.
6. Apaydin S., Sariyar M., Erek E., Ataman R., Yiğitbaş R., Hamzaoğlu I., et al. Hypercalcemia and hyperparathyroidism after renal transplantation. Nephron 1999, 81:364-365.
7. McHenry C.R., Mostafavi K., Murphy T.A. Tertiary hyperparathyroidism attributable to long-term oral phosphate therapy. Endocr Pract 2006, 12:294-298.
8. Marx J., Attie M.F., Spiegel A.M., Levine M.A., Lasker R.D., Fox M. An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N Engl J Med 1982, 306:257-264.
9. Christensen S.E., Nissen P.H., Vestergaard P., Mosekilde L. Familial hypocalciuric hypercalcaemia: a review. Curr Opin Endocrinol Diabetes Obes 2011, 18:359-370.
10. Nesbit M.A., Hannan F.M., Howles S.A., Reed A.A., Cranston T., Thakker C.E., et al. Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet 2013, 45:93-97.
11. Tonyushkina K.T., O'Connor S.O., Dunbar N.S. A novel CaSR mutation presenting as a severe case of neonatal familial hypocalciuric hypercalcemia. Int J Pediatr Endocrinol 2012, 2012(1).
12. Albright F. Case records of the Massachusetts General Hospital-Case 39061. N Engl J Med 1941, 225:789-796.
13. Suva L.J., Winslow G.A., Wettenhall R.E.H., Hammonds R.G., Moseley J.M., Diefenbach-Jagger H., et al. A parathyroid hormone-related protein implicated in malignant hypercalcemixa: cloning and expression. Science 1987, 237:893-897.
14. Clines G.A. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 2011, 18:330-346.
15. McCauley L.K., Martin T.J. Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res 2012, 27:1231-1239.
16. Srirajaskanthan R., McStay M., Toumpanakis C., Meyer T., Caplin M.E. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review. Neuroendocrinology 2009, 89:48-55.
17. Takasaki H., Kanamori H., Takabayashi M., Yamaji S., Koharazawa H., Taguchi J., et al. Non-Hodgkin's lymphoma presenting as multiple bone lesions and hypercalcemia. Am J Hematol 2006, 81:439-442.
18. Montgrain P.R., Deftos L.J., Arenberg D., Tipps A., Quintana R., Carskadon S., et al. Prognostic implications of parathyroid hormone-related protein in males and females with non-small-cell lung cancer. Clin Lung Cancer 2011, 12:197-205.
19. Schwartz G.G., Skinner H.G. Prospective studies of total and ionized serum calcium in relation to incident and fatal ovarian cancer. Gynecol Oncol 2013, 129:169-172.
20. DeLellis R.A., Xia L. Paraneoplastic endocrine syndromes: a review. Endocr Pathol 2003, 14:303-317.
21. Horwitz M.J., Tedesco M.B., Sereika S.M., Hollis B.W., Garcia-Ocaña A., et al. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. Clin Endocrinol Metab 2003, 88:1603-1609.
22. Wongdee K., Krishnamra N., Charoenphandhu N.J. Endochondral bone growth, bone calcium accretion, and bone mineral density: how are they related?. Physiol Sci 2012, 62:299-307.
23. Macica C., Liang G., Nasiri A., Broadus A.E. Genetic evidence of the regulatory role of parathyroid hormone-related protein in articular chondrocyte maintenance in an experimental mouse model. Arthritis Rheum 2011, 63:3333-3343.
24. Raison D., Coquard C., Hochane M., Steger J., Massfelder T., Moulin B., et al. Knockdown of parathyroid hormone related protein in smooth muscle cells alters renal hemodynamics but not blood pressure. Am J Physiol Renal Physiol 2013, 305:F333-F342.
25. Bilici A., Doventas A., Karadag B., Hekim N. Hypercalcemia associated with a uterine leiomyoma: a case report and review of the literature. Gynecol Oncol 2004, 93:269-271.
26. Srivastava T., Kats A., Martin T.J., Pompolo S., Alon U.S. Parathyroid-hormone-related protein-mediated hypercalcemia in benign congenital mesoblastic nephroma. Pediatr Nephrol 2011, 26:799-803.
27. Takeda K., Hara N., Kawaguchi M., Nishiyama T., Takahashi K. Parathyroid hormone-related peptide-producing non-familial pheochromocytoma in a child. Int J Urol 2010, 17:673-676.
28. Eller-Vainicher C., Ossola M.W., Beck-Peccoz P., Chiodini I. PTHrP-associated hypercalcemia of pregnancy resolved after delivery: a case report. Eur J Endocrinol 2012, 166:753-756.
29. Segal E., Hochberg I., Weisman Y., Ish-Shalom S. Severe postpartum osteoporosis with increased PTHrP during lactation in a patient after total thyroidectomy and parathyroidectomy. Osteoporos Int 2011, 22:2907-2911.
30. Sato K. Hypercalcemia during pregnancy, puerperium, and lactation: review and a case report of hypercalcemic crisis after delivery due to excessive production of PTH-related protein (PTHrP) without malignancy (humoral hypercalcemia of pregnancy). Endocr J 2008, 55:959-966.
31. van Wingerden J.J. Gigantomastia-definition and association with hypercalcaemia. J Plast Reconstr Aesthet Surg 2009, 62:112-114.
32. Adams J.S., Hewison M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 2012, 523:95-102.
33. Kallas M., Green F., Hewison M., White C., Kline G. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J Clin Endocrinol Metab 2010, 95:3111-3117.
34. Hewison M., Kantorovich V., Liker H.R., Van Herle A.J., Cohan P., Zehnder D., et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res 2003, 18:579-582.
35. Karakelides H., Geller J.L., Schroeter A.L., Chen H., Behn P.S., Adams J.S., et al. Vitamin D-mediated hypercalcemia in slack skin disease: evidence for involvement of extrarenal 25-hydroxyvitamin D 1alpha-hydroxylase. J Bone Miner Res 2006, 21:1496-1499.
36. Hibi M., Hara F., Tomishige H., Nishida Y., Kato T., Okumura N., et al. 1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol 2008, 25:73-78.
37. Hamzeh N. Sarcoidosis. Med Clin North Am 2011, 95:1223-1234.
38. Zhang J.T., Chan C., Kwun S.Y., Benson K.A.J. A case of severe 1,25-dihydroxyvitamin D-mediated hypercalcemia due to a granulomatous disorder. Clin Endocrinol Metab 2012, 97:2579-2583.
39. Sfriso P., Caso F., Tognon S., Galozzi P., Gava A., Punzi L. Blau syndrome, clinical and genetic aspects. Autoimmun Rev 2012, 12:44-51.
40. Al-Ali H., Yabis A.A., Issa E., Salem Z., Tawil A., Khoury N., et al. Hypercalcemia in Langerhans' cell granulomatosis with elevated 1,25 dihydroxyvitamin D (calcitriol) level. Bone 2002, 30:331-334.
41. Jurney T.H. Hypercalcemia in a patient with eosinophilic granuloma. Am J Med 1984, 76:527-528.
42. Dehner L.P. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003, 27:579-593.
43. Ioachimescu A.G., Bauer T.W., Licata A. Active Crohn disease and hypercalcemia treated with infliximab: case report and literature review. Endocr Pract 2008, 14:87-92.
44. Del Porto F., Proietta M., Koverech A., Trappolini M., Aliberti G. Hypercalcaemia in systemic lupus erythematosus. Lupus 2011, 20:758-762.
45. Bosch X., López-Soto A., Morelló A., Olmo A., Urbano-Márquez A. Vitamin D metabolite-mediated hypercalcemia in Wegener's granulomatosis. Mayo Clin Proc 1997, 72:440-444.
46. Sharma S.C. Serum calcium in pulmonary tuberculosis. Post-Grad Med J 1981, 57:694-696.
47. Roussos A., Lagogianni I., Gonis A., Ilias I., Kazi D., Patsopoulos D., et al. Hypercalcaemia in Greek patients with tuberculosis before the initiation of anti-tuberculosis treatment. Respir Med 2001, 95:187-190.
48. Deniz O., Tozkoparan E., Yonem A., Ciftci F., Bozkanat E., Cakir E., et al. Low parathormone levels and hypercalcaemia in patients with pulmonary tuberculosis: relation to radiological extent of disease and tuberculin skin test. Int J Tuberc Lung Dis 2005, 9:317-321.
49. Spindel S.J., Hamill R.J., Georghiou P.R., Lacke C.E., Green L.K., Mallette L.E. Case report: vitamin D-mediated hypercalcemia in fungal infections. Am J Med Sci 1995, 310:71-76.
50. Khasawneh F.A., Ahmed S., Halloush R.A. Progressive disseminated histoplasmosis presenting with cachexia and hypercalcemia. Int J Gen Med 2013, 6:79-83.
51. Huang J.C., Kuo M.C., Hwang S.J., Hwang D.Y., Chen H.C. Vitamin D-mediated hypercalcemia as the initial manifestation of pulmonary cryptococcosis in an HIV-uninfected patient. Intern Med 2012, 51:1793-1796.
52. Chatzikyrkou C., Clajus C., Haubitz M., Hafer C. Hypercalcemia and pneumocystis Pneumonia after kidney transplantation: report of an exceptional case and literature review. Transpl Infect Dis 2011, 13:496-500.
53. Fierer J., Burton D.W., Haghighi P., Deftos L.J. Hypercalcemia in disseminated coccidioidomycosis: expression of parathyroid hormone-related peptide is characteristic of granulomatous inflammation. Clin Infect Dis 2012, 55:e61-e66.
54. Shahnaz S., Reich D., Arévalo-Valencia D., Kucinska S., Tulczynska J., Fleischman J. HTLV-1-associated adult T cell leukemia lymphoma presenting as granulomatous pneumocystis jiroveci pneumonia (PJP) and hypercalcemia. J Gen Intern Med 2007, 22:420-423.
55. Tashiro K., Abe T., Oue N., Yasui W., Ryoji M. Characterization of vitamin D-mediated induction of the CYP 24 transcription. Mol Cell Endocrinol 2004, 226:27-32.
56. St-Arnaud R., Arabian A., Travers R., Barletta F., Raval-Pandya M., Chapin K., et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxy-vitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000, 141:2658-2666.
57. Schlingmann K.P., Kaufmann M., Weber S., Irwin A., Goos C., John U., et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011, 365:410-421.
58. Streeten E.A., Zarbalian K., Damcott C.M. CYP24A1 mutations in idiopathic infantile hypercalcemia. N Engl J Med 2011, 365:1741-1742.
59. Tebben P.J., Milliner D.S., Horst R.L., Harris P.C., Singh R.J., Wu Y., et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 2012, 97:E423-E427.
60. Dauber A., Nguyen T.T., Sochett E., Cole D.E., Horst R., Abrams S.A., et al. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab 2012, 97:E268-E274.
61. Fencl F., Bláhová K., Schlingmann K.P., Konrad M., Seeman T. Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene. Eur J Pediatr 2013, 172:45-49.
62. Skalova S., Cerna L., Bayer M., Kutilek S., Konrad M., Schlingmann K.P. Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia. Iran J Kidney Dis 2013, 7:160-164.
63. Castanet M., Mallet E., Kottler M.L. Lightwood syndrome revisited with a novel mutation in CYP24 and vitamin d supplement recommendations. J Pediatr 2013, 163:1208-1210.
64. Dinour D., Beckerman P., Ganon L., Tordjman K., Eisenstein Z., Holtzman E.J. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 2013, 190:552-557.
65. Nesterova G., Malicdan M.C., Yasuda K., Sakaki T., Vilboux T., Ciccone C., et al. 1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol 2013, 8:649-657.
66. Babatunde B.O. Multiple myeloma/hypercalcemia. Arthritis Res Ther 2007, 9:S4.
67. Khalil Al-Fars Multiple myeloma: an update. Oman Med J 2013, 28:3-11.
68. Shimizu H., Monden T., Tomotsune T., Nakatani Y., Domeki N., Matsumura M., et al. A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α). Intern Med 2011, 50:2993-2996.
69. Cafforio P., Savonarola A., Stucci S., De Matteo M., Tucci M., Brunetti A.E., et al. PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression. J Bone Miner Res 2014, 29:55-66.
70. Sam R., Vaseemuddin M., Siddique A., Haghighat L., Kazlauskaite R., An G., et al. Hypercalcemia in patients in the burn intensive care unit. J Burn Care Res 2007, 28:742-746.
71. Sato Y., Honda Y., Iwamoto J., Kanoko T., Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov Disord 2005, 20:1598-1603.
72. Goldsmith R.S. Calcium metabolism under stress and in repose. Life Sci Space Res 1972, 10:87-101.
73. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
74. McColm J., Hu L., Womack T., Tang C.C., Chiang A.Y. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014, 29:935-943.
75. Iqbal A.A., Burgess E.H., Gallina D.L., Nanes M.S., Cook C.B. Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocr Pract 2003, 9:517-521.
76. Medarov B.I. Milk alkali syndrome. Mayo Clin Proc 2009, 84:261-267.
77. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77:204-210.
78. Araki T., Holick M.F., Alfonso B.D., Charlap E., Romero C.M., Rizk D., et al. Vitamin D intoxication with severe hypercalcemia due to manufacturing and labeling errors of two dietary supplements made in the United States. J Clin Endocrinol Metab 2011, 96:3603-3608.
79. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008, 88:582S-586S.
80. Deluca H.F., Prahl J.M., Plum L.A. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch Biochem Biophys 2011, 505:226-230.
81. Ong L.M., Narayanan P., Goh H.K., Manocha A.B., Ghazali A., Omar M., et al. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Nephrology (Carlton) 2013, 18:194-200.
82. Graziani G., Calvetta A., Cucchiari D., Valaperta S., Montanelli A. Life-threatening hypercalcemia in patients with rhabdomyolysis-induced oliguric acute renal failure. J Nephrol 2011, 24:128-131.
83. Bryowsky J.J., Bugnitz M.C., Hak E.B. Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition. Pharmacotherapy 2004, 24:939-944.
84. Katahira M., Yamada T., Kawai M. A case of Cushing syndrome with both secondary hypothyroidism and hypercalcemia due to postoperative adrenal insufficiency. Endocr J 2004, 51:105-113.
85. Nerup J. Addison's disease-clinical studies. A report of 108 cases. Acta Endocrinol (Copenh) 1974, 76:127-141.
86. Montoli A., Colussi G., Minetti L. Hypercalcemia in Addison's disease: calciotropic hormone profile and bone histology. J Intern Med 1992, 232:535-540.
87. Tsao Y.T., Lee S.W., Hsu J.C., Ho F.M., Wang W.J. Surviving a crisis of HIV-associated immune reconstitution syndrome. Am J Emerg Med 2012, 30:1661.
88. Shu S.T., Martin C.K., Thudi N.K., Dirksen W.P., Rosol T.J. Osteolytic bone resorption in adult T-cell leukemia/lymphoma. Leuk Lymphoma 2010, 51:702-714.
89. Kampfenkel T., Baraniskin A., Teschendorf C., Schmiegel W., Massenkeil G. A rare case of chronic lymphocytic leukemia with hypercalcemia induced by elevated parathyroid hormone-related peptides. Acta Haematol 2010, 124:57-60.
90. Bhalla K., Ennis D.M., Ennis E.D. Hypercalcemia caused by iatrogenic hypervitaminosis A. J Am Diet Assoc 2005, 105:119-121.
91. Letavernier E., Rodenas A., Guerrot D., Haymann J.P. Williams-Beuren syndrome hypercalcemia: is TRPC3 a novel mediator in calcium homeostasis?. Pediatrics 2012, 129:e1626-e1630.
92. Escribano J., Balaguer A., Pagone F., Feliu A., Roqué I., Figuls M. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane Database Syst Rev 2009, (1). CD004754.
93. Wermers R.A., Kearns A.E., Jenkins G.D., Melton L.J. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med 2007, 120:911.
94. Lally J., Lee B., McDonald C. Prevalence of hypercalcaemia in patients on maintenance lithium therapy monitored in primary care. Ir Med J 2013, 106:15-17.
95. Albert U., De Cori D., Aguglia A., Barbaro F., Lanfranco F., Bogetto F., Maina G. Lithium-associated hyperparathyroidism and hypercalcaemia: a case-control cross-sectional study. J Affect Disord 2013, 151:786-790.
96. McHenry C.R., Lee K. Lithium therapy and disorders of the parathyroid glands. Endocr Pract 1996, 2:103-109.
97. Haden S.T., Stoll A.L., McCormick S., Scott J., Fuleihan G.el-H. Alterations in parathyroid dynamics in lithium-treated subjects. Clin Endocrinol Metab 1997, 82:2844-2848.
98. Mallette L.E., Khouri K., Zengotita H., Hollis B.W., Malini S. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab 1989, 68:654-660.
99. Marti J.L., Yang C.S., Carling T., Roman S.A., Sosa J.A., Donovan P., et al. Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Ann Surg Oncol 2012, 19:3465-3471.
100. Lehmann S.W., Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know?. J Affect Disord 2013, 146:151-157.
101. Khandwala H.M., Van Uum S. Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature. Endocr Pract 2006, 12:54-58.